A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent.
Aged 18-75 years (inclusive).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20.
None
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor
Nanjing Legend Biotech Co.
Collaborator